Our findings are consistent with reports that in neuroblastoma and mantle cell lymphoma, where downregulation of MYC upon HSP90 inhibition was associated with loss of tumor cell proliferation, cell cycle arrest, increased apoptosis, and upregulation of tumor suppressors, such as p53 [14,31]. The gene discussed is MYC; the disease is mantle cell lymphoma.